{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis+to+Lung&page=2", "query": { "condition": "Metastasis to Lung", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastasis+to+Lung&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:08:55.305Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03138889", "title": "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "NKTR-214", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2017-06-09", "completion_date": "2022-08-24", "has_results": true, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 23, "location_summary": "Fayetteville, Arkansas • San Francisco, California • Aurora, Colorado + 19 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138889" }, { "nct_id": "NCT04886804", "title": "Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "zongertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 608, "start_date": "2021-07-02", "completion_date": "2028-08-30", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886804" }, { "nct_id": "NCT02352948", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non - Small Cell Lung Cancer NSCLC" ], "interventions": [ { "name": "MEDI4736 (durvalumab)", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)", "type": "DRUG" }, { "name": "tremelimumab (anti-CTLA4)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 597, "start_date": "2015-01-13", "completion_date": "2023-08-30", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 33, "location_summary": "Chandler, Arizona • Anaheim, California • Duarte, California + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02352948" }, { "nct_id": "NCT06362369", "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Melanoma", "Metastasis", "Pleural Mesothelioma", "Renal Cell Carcinoma", "MSI-High", "Mismatch Repair Deficiency", "Colorectal Cancer", "Hepatocellular Carcinoma", "Hepatocellular Cancer", "Renal Cell Cancer", "Kidney Cancer", "Skin Cancer", "Non Small Cell Lung Cancer", "NSCLC", "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations", "ALK Genomic Tumor Aberrations" ], "interventions": [ { "name": "Alintegimod", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "7 Hills Pharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2024-08-23", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 5, "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06362369" }, { "nct_id": "NCT06793215", "title": "A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "KRAS G12C Lung Cancer" ], "interventions": [ { "name": "Divarasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2025-10-24", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 50, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Greenbrae, California + 47 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06793215" }, { "nct_id": "NCT04659122", "title": "A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19", "Undefined" ], "interventions": [ { "name": "AT-100", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Airway Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-08-17", "completion_date": "2023-02-23", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04659122" }, { "nct_id": "NCT06464562", "title": "LiveWell: Adapted DBT Skills Training for Metastatic Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Metastatic to Lung" ], "interventions": [ { "name": "LiveWell: Adapted Dialectical Behavioral Therapy Skills Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2025-02-14", "completion_date": "2025-08-06", "has_results": true, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06464562" }, { "nct_id": "NCT05973773", "title": "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2023-12-18", "completion_date": "2027-05-27", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 9, "location_summary": "Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more", "locations": [ { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973773" }, { "nct_id": "NCT03940703", "title": "A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tepotinib", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2019-09-19", "completion_date": "2026-05-01", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 49, "location_summary": "Yuma, Arizona • Fountain Valley, California • Long Beach, California + 43 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03940703" }, { "nct_id": "NCT04197934", "title": "WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma, IDH-Wildtype", "Glioblastoma, IDH-Wildtype", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Central Nervous System", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection - blood samples", "type": "PROCEDURE" }, { "name": "Biospecimen Collection - CSF samples", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "EGFR/EGFRvIII Inhibitor WSD0922-FU", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-12-20", "completion_date": "2031-02-06", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-11T04:08:55.305Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04197934" } ] }